SCHEMBL6098776

SCHEMBL6098776

CC(C)(C)OC(=O)C(N)C(=O)n1cc(C2=CC(=O)NC2=O)c2cc(OCc3ccccc3)ccc21

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LTA4H P09960 2/20 0.39
MAOB P27338 4/20 0.37
MAOA P21397 3/20 0.37
BAZ2B Q9UIF8 1/20 0.36
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
PLA2G2A P14555 2/20 0.35
HSP90AA1 P07900 1/20 0.35
HSP90AB1 P08238 1/20 0.35
GHSR Q92847 3/20 0.35
SRD5A2 P31213 1/20 0.35
PPARG P37231 1/20 0.34
PPARD Q03181 1/20 0.34
PPARA Q07869 1/20 0.34
LTB4R Q15722 1/20 0.34
LTB4R2 Q9NPC1 1/20 0.34
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34
CNR1 P21554 1/20 0.34
CNR2 P34972 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6098773 0.83 MAOB (0.37) MAOBMAOABAZ2BGHSRSRD5A2
SCHEMBL6098735 0.83 BAZ2B (0.48) MAOBMAOABAZ2BMEN1KMT2A
SCHEMBL6100670 0.80 MAOB (0.43) MAOBMAOASRD5A2
SCHEMBL6098654 0.76 NPC1 (0.41) MAOBMAOAPPARGPPARDPPARA
SCHEMBL6099369 0.76 KDM4E (0.42) MAOBMAOAPLA2G2APPARGPPARD
SCHEMBL6799799 0.76 PPARG (0.41) MAOBMAOAMEN1KMT2ASRD5A2
SCHEMBL6098592 0.75 PPARD (0.48) MAOBMAOAPLA2G2APPARGPPARD
SCHEMBL6097466 0.74 MAOB (0.44) MAOBMAOAMEN1KMT2ASRD5A2
SCHEMBL6099511 0.71 MAOB (0.41) MAOBMAOAMEN1KMT2APPARG
SCHEMBL6099154 0.71 HTR6 (0.52) MAOBMAOAMEN1KMT2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7129250-B2 Neuroprotective and anti-proliferative compounds AEGERA THERAPEUTICS INC. (CA) 2006-10-31 US disclosed
US-20040220202-A1 Neuroprotective and anti-proliferative compounds AEGERA THERAPEUTICS INC. (CA) 2004-11-04 US disclosed
US-20040102467-A1 Neuroprotective and anti-proliferative compounds AEGERA THERAPEUTICS INC. (CA) 2004-05-27 US disclosed
EP-1283836-A2 NEUROPROTECTIVE AND ANTI-PROLIFERATIVE COMPOUNDS Aegera Therapeutics Inc. (CA) 2003-02-19 EP disclosed
WO-2001087887-A2 NEUROPROTECTIVE AND ANTI-PROLIFERATIVE COMPOUNDS AEGERA THERAPEUTICS INC. (CA) 2001-11-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040220202-A1 Neuroprotective and anti-proliferative compounds NLN, MKI67, BDNF LTA4H 3738/4885MAOB 859/4885MAOA 1148/4885
US-20040102467-A1 Neuroprotective and anti-proliferative compounds MKI67, NLN, BDNF LTA4H 3821/4885MAOB 895/4885MAOA 1264/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.